Chemotherapy-induced nausea and vomiting: Clinician and patient perspectives

Journal of Supportive Oncology

Volumn 5, Issue 2 SUPPL. 1, 2007, Pages 5-12

  Schwartzberg, Lee S ^a,b  

^a WEST CLINIC   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APREPITANT; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEXAMETHASONE; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; DOXORUBICIN; GEMCITABINE; GRANISETRON; IRINOTECAN; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; OXALIPLATIN; PALONOSETRON; PHENOTHIAZINE; PLACEBO; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; SEROTONIN ANTAGONIST; TRASTUZUMAB; TROPISETRON; UNINDEXED DRUG;

AGE; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; COST OF ILLNESS; DISEASE CLASSIFICATION; DRUG BINDING; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DYSPEPSIA; GENDER; HEALTH CARE COST; HOSPITAL COST; HUMAN; INCIDENCE; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; HUMANS; NAUSEA; NEOPLASMS; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; VOMITING;

EID: 33847363278     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. O'Brien BJ, Rusthoven J, Rocchi A, et al. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ 1993;149:296-302.
2. Osoba D, Zee B, Warr D, et al. Effect of post-chemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997;5:307-313.
3. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988;6:1746-1752.
4. Morran C, Smith DC, Anderson DA, McArdle CS. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. Br Med J 1979;1:1323-1324.
5. Clavel M, Soukop M, Greenstreet YL. Improved control of emesis and quality of life with ondansetron in breast cancer. Oncology 1993;50:180-185.
6. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995;13:1036-1043.
7. Demoor C, Cohen L, Eisenberg PD, et al. Oncologists' compliance with antiemetic guidelines (AEG) and outcomes of patients (pts) receiving emetogenic chemotherapy (CT). Proc Am Soc Clin Oncol 2003;22:2924.
8. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004;15:526-536.
9. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:1289-1294.
10. American Society of Clinical Oncology; Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-2947.
11. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729-764.
12. Antiemesis. NCCN Clinical Practice Guidelines in Oncology v.2.2006. Available at http://www.nccn.org. Accessed January 8, 2007.
13. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999;4:191-196.
14. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 2005;13:80-84.
15. Grunberg SM. Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. Blood Rev 1989;3:216-221.
16. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991;83:613-620.
17. Gralla RJ, Roila F, Tonato M, et al. Consensus conference on antiemetic therapy. Multinational Association for Supportive Care in Cancer. Perugia, Italy. March 29-31, 2004. Available at: http://www.mascc.org. Accessed January 8, 2007.
18. Perez EA, Hesketh P, Sandbach J, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998;16:754-760.
19. Hickok JT, Roscoe JA, Morrow GR, et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 2003;97:2880-2886.
20. Hickok JT, Roscoe JA, Morrow GR, et al. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 2005;6:765-772.
21. 3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother 2003;4:2297-2303.
22. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-1577.
23. 3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98:2473-2482.
24. Rubenstein EB, Gralla RJ, Eisenberg P, et al. Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute & delayed chemotherapy-induced nausea and vomiting (CINV): combined results of two phase III trials. Proc Am Soc Clin Oncol 2003;22:2932.
25. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-1449.
26. Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J Support Oncol 2006;4:467-471.
27. Navari RM. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials. Cancer Invest 2004;22:569-576.
28. Massaro AM, Lenz KL. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother 2005;39:77-85.
29. Hesketh PJ, Grunberg SM, Gralla RJ, et al; Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-4119.
30. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-2830.
31. Grote T, Hajdenberg J, Cartmell A, et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006;4:403-408.
32. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-2268.
33. Grunberg SM, Vanden Burgt A, Berry S, et al. Prevention of delayed nausea and vomiting (D-CINV): carryover effect analysis of pooled data from 2 phase III studies of palonosetron (PALO). Proc Am Soc Clin Oncol 2004;22(14S):8051.
34. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-4478.
35. Vanscoy GJ, Fortner B, Smith R, Weber R, Rihn TL. Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics. Community Oncol 2005;2:127-132.